Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Benralizumab for the Prevention of COPD Exacerbations

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Erythropoietin in Preterm Infants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association between Mental Disorders and Subsequent Medical Conditions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Fertility Treatment Resulting in Live Births in Women with Asthma - Associated with Perennial Allergy?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. International Severe Asthma Registry: Mission Statement

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. NORDSTAR - Paving the way for a new era in asthma research

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Clinical characteristics of the BREATHE cohort - a real-life study on patients with asthma and COPD

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Primary ciliary dyskinesia patients have the same P. aeruginosa clone in sinuses and lungs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • GALATHEA and TERRANOVA Study Investigators
Vis graf over relationer

BACKGROUND: The efficacy and safety of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.

METHODS: In the GALATHEA and TERRANOVA trials, we enrolled patients with COPD (at a ratio of approximately 2:1 on the basis of eosinophil count [≥220 per cubic millimeter vs. <220 per cubic millimeter]) who had frequent exacerbations despite receiving guideline-based inhaled treatment. Patients were randomly assigned to receive benralizumab (30 or 100 mg in GALATHEA; 10, 30, or 100 mg in TERRANOVA) every 8 weeks (every 4 weeks for the first three doses) or placebo. The primary end point was the treatment effect of benralizumab, measured as the annualized COPD exacerbation rate ratio (benralizumab vs. placebo) at week 56 in patients with baseline blood eosinophil counts of 220 per cubic millimeter or greater. Safety was also assessed.

RESULTS: In GALATHEA, the estimates of the annualized exacerbation rate were 1.19 per year (95% confidence interval [CI], 1.04 to 1.36) in the 30-mg benralizumab group, 1.03 per year (95% CI, 0.90 to 1.19) in the 100-mg benralizumab group, and 1.24 per year (95% CI, 1.08 to 1.42) in the placebo group; the rate ratio as compared with placebo was 0.96 for 30 mg of benralizumab (P = 0.65) and 0.83 for 100 mg of benralizumab (P = 0.05). In TERRANOVA, the estimates of the annualized exacerbation rate for 10 mg, 30 mg, and 100 mg of benralizumab and for placebo were 0.99 per year (95% CI, 0.87 to 1.13), 1.21 per year (95% CI, 1.08 to 1.37), 1.09 per year (95% CI, 0.96 to 1.23), and 1.17 per year (95% CI, 1.04 to 1.32), respectively; the corresponding rate ratios were 0.85 (P = 0.06), 1.04 (P = 0.66), and 0.93 (P = 0.40). At 56 weeks, none of the annualized COPD exacerbation rate ratios for any dose of benralizumab as compared with placebo reached significance in either trial. Types and frequencies of adverse events were similar with benralizumab and placebo.

CONCLUSIONS: Add-on benralizumab was not associated with a lower annualized rate of COPD exacerbations than placebo among patients with moderate to very severe COPD, a history of frequent moderate or severe exacerbations, and blood eosinophil counts of 220 per cubic millimeter or greater (Funded by AstraZeneca [GALATHEA and TERRANOVA] and Kyowa Hakko Kirin [GALATHEA]; GALATHEA and TERRANOVA ClinicalTrials.gov numbers, NCT02138916 and NCT02155660.).

OriginalsprogEngelsk
TidsskriftThe New England journal of medicine
Sider (fra-til)1023-1034
ISSN0028-4793
DOI
StatusUdgivet - 20 maj 2019

Bibliografisk note

Copyright © 2019 Massachusetts Medical Society.

ID: 57232235